[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601160":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":28,"responsibleParty":45,"collaborators":10,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":10,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":10,"overallStatus":30,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Clindove Research LLC","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All Participants",null,"Participants undergoing metabolic and\u002For psychiatric assessments through blood work and structured clinical evaluations, as outlined in the study protocol.",[13],"Other: Blood Work",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Blood Work","Collection of blood samples for metabolic and other necessary biomarker analysis, including Hemoglobin A1c (HbA1c), Lipid Panel, Liver and Kidney function tests and other protocol-defined assays.",[9],[20],{"name":21,"affiliation":5,"role":22},"Nelly Cohen, MD","PRINCIPAL_INVESTIGATOR",[24],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},"CONTACT","516-518-3239","study@clindoveresearch.com",[29],{"facility":5,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Brooklyn","New York","11221","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-73.94958,40.6501,{"lat":40,"lon":39},[43,44],{"name":21,"role":25,"phone":26,"phoneExt":10,"email":27},{"name":21,"role":22,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100601160","non-interventional-pre-screening-protocol-aims-to-evaluate-participants-for-potential-trial-eligibility-in-future-clinical-trialsstudies-focusing-on-metabolic-and-psychiatric-health-100601160",false,"NCT07106879","Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials\u002FStudies Focusing on Metabolic and Psychiatric Health.","Pre-screening Survey for Metabolic, Cardiovascular, Obesity, Mental Health, and Endocrine Trial Eligibility (DOVE-MET-COME-100)","Inclusion Criteria:\n\n* Any participant of age 18 years and over\n* Who are willing to provide informed consent and participate in the pre-screening study and comply with study procedures.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding individuals\n* Individuals having severe cognitive impairment or inability to provide informed consent\n* Individuals having acute psychiatric emergencies requiring immediate intervention\u002Fhospitalization\n* Individuals who are currently participating in another research study that conflicts with pre-screening data collection\n* Individuals having known history of drug\u002Falcohol misuse\n* Individuals having medical conditions that, in the investigator's opinion, could compromise the integrity of the screening process or pose significant risks to the participant's health.",true,"ALL","18 Years",{"count":58,"type":59},7000,"ESTIMATED","5 Years","OBSERVATIONAL","DOVE-MET-COME-100 is a single site prescreening survey study designed to identify adults who may be eligible for future industry-sponsored clinical trials. A physician will oversee the informed consent process, after which participants will be surveyed on demographics, medical history, current health conditions and symptoms. The study team may also collect basic health information, including vital signs, urine drug tests, blood samples and pregnancy tests (if applicable). A physician will review each participant's medical history in a one-on-one interview to assess potential fit for upcoming trials. If needed, the doctor may contact the participant's current doctors or pharmacies to gather more information for eligibility review.",[64,65,66,67,68,69,70,71],"Cardiovascular Diseases","Metabolic Syndrome","Obesity","Prediabetes","Mental Health Disorders","Endocrine Dysfunction","Type 2 Diabetes Mellitus (T2DM)","Chronic Kidney Disease (CKD)","2025-08-11",{"date":74,"type":75},"2025-08-12","ACTUAL",{"date":77,"type":75},"2025-07-30",{"date":79,"type":59},"2030-12-01",{"name":5,"class":6},1]